Clinical Trial Update: Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD) [Phase 1]

View source ↗

Summary

A Phase 1 study of genome-edited hematopoietic stem and progenitor cell therapy for sickle cell disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Genome-edited hematopoietic stem and progenitor cell therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease | Phase 1 | Status: TERMINATED